
|Podcasts|November 16, 2021
Facilitating Decentralized Clinical Trials with the Direct-to-Patient Trial Strategy
Author(s)YPrime
A direct-to-patient (DtP) clinical trial design, where investigational medicinal products (IMP) and clinical supplies are shipped or delivered directly to patients, fits within a decentralized clinical trial (DCT) model. Although patients, sites, and sponsors can all benefit from this trial design, there are unique complexities to DtP trials, that can be managed with advanced technology. Learn about this trial strategy, the unique challenges, what the industry is doing to address these challenges and how technology can help facilitate adoption of this trial design.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
2
Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run
3
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
4
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
5



